Neuspera Medical Inc.

We’re excited to welcome Steve Paul as Chief Commercial Officer at Neuspera! Steve brings deep experience scaling commercial organizations and a strong track record of launching category-defining medical technologies. He joins Neuspera at a pivotal time as we prepare to bring our initial innovation to market: the first wireless, battery-free, ultra-miniaturized percutaneous sacral neuromodulation (pSNM) device for urgency urinary incontinence (UUI), currently pending FDA approval. Steve will lead our commercial strategy and team-building efforts as we move toward launch and expand access to this much-needed solution. Join us in welcoming Steve to the team as we continue advancing the future of bioelectronic medicine. For Investigational Use Only. #Neuspera #pSNM #UUI #MedTech #BioelectronicMedicine

Neuspera’s six-month pivotal trial data shows that our battery-free percutaneous sacral neuromodulation (pSNM) system has similar effectiveness rates as traditional sacral neuromodulation (SNM) devices — while aiming to provide a significantly better patient experience for urgency urinary incontinence (UUI). Note: Neuspera’s device is for Investigational Use Only.   🔗 Learn more here: https://lnkd.in/g6HhHinu   #Urology #UUI #MedTech #ClinicalTrial

Neuspera Medical is delighted to announce that the primary endpoint results of our Pivotal Phase II SANS UUI clinical study have been accepted for podium presentation during SUFU’s annual winter meeting, February 26 – March 1, 2025, in Rancho Mirage, California.  Our SANS-UUI National PI, Dr. Osvaldo Padron will present “TREATMENT OF OAB SYMPTOMS USING NEUSPERA’S ULTRA-MINIATURIZED SYSTEM: 6-MONTH RESULTS OF THE SANS-UUI PHASE II STUDY” at 8:00AM during the OAB/Chemodenervation Podium Session, 7:30-9:00AM on Saturday, March 1st. The full SUFU program schedule can be viewed online. https://lnkd.in/gqsTBTw3 We hope to see you there! #SUFU #OAB #Urology

Neuspera is looking forward to participating and presenting at the Piper Sandler 36th Annual Healthcare Conference early December. Steffen Hovard will provide an update on the progress and positive momentum for Neuspera in getting PMA approval for our micro-invasive system for treatment of overactive bladder. #PSCHealthcare2024 #OAB #Urology #Innovation

Neuspera CEO Steffen Hovard talks activity and alignment with Medsider. https://lnkd.in/gixvKDf8 #NeusperaSystem #neuromodulation #medicaldevice #incontinence

We are excited that the September 2024 issue of Urology Times included an update on the progress of our SANS UUI clinical trial. https://lnkd.in/gpakHCjY #NeusperaSystem #urology #incontinence #neuromodulation

We're live in DC at AUGS! Our CEO and CMO, Steffen Hovard and Dr. Steven Siegel are excited to meet with key physicians and researchers at American Urogynecologic Society PFD Week as we gear up for our planned U.S. market introduction of the Neuspera System to treat symptoms of OAB in 2025. Hope to see you here!  #PFDweek #NeusperaSystem #urology #incontinence #neuromodulation

Our CEO and CMO, Steffen Hovard and Dr. Steven Siegel will be heading to Washington D.C. for this year’s American Urogynecologic Society PFD Week and are looking forward to connecting with old friends and meeting new ones. Reach out via LinkedIn or email to meet up. Hope to see you there!    #PFDweek #NeusperaSystem #urology #incontinence #neuromodulation